Last updated: October 20, 2026
Dupilumab, marketed as Dupixent by Sanofi and Regeneron, is one of the largest biologic franchises in immunology. Sanofi reported Dupixent net sales of €13.1 billion in 2024, up from €10.7 billion in 2023 and €8.3 billion in 2022. Growth is driven by additional indications, broader treatment adoption, pediatric approvals, and expansion into chronic obstructive pulmonary disease (COPD). The principal medium-term risk is not near-term biosimilar entry but increasing competition from oral immunomodulators, next-generation biologics, and eventual BPCIA litigation.
How large is the dupilumab market?
Dupilumab is a fully human monoclonal antibody that blocks signaling through the interleukin-4 receptor alpha subunit. This inhibits both IL-4 and IL-13 pathways, which are central to type 2 inflammation.
Dupixent is approved or marketed across multiple inflammatory diseases:
| Indication |
Initial U.S. approval |
Commercial relevance |
| Moderate-to-severe atopic dermatitis |
2017 |
Original and largest patient base |
| Moderate-to-severe asthma |
2018 |
Major expansion into respiratory medicine |
| Chronic rhinosinusitis with nasal polyps |
2019 |
High-value specialist market |
| Eosinophilic esophagitis |
2022 |
First FDA-approved biologic for the disease |
| Prurigo nodularis |
2022 |
Orphan-like, high-unmet-need market |
| Eosinophilic COPD |
2024 |
New respiratory growth driver |
The COPD approval is strategically important because it expands dupilumab beyond asthma into a large population with limited targeted biologic treatment options. The FDA approved Dupixent in September 2024 as an add-on maintenance treatment for adults with uncontrolled COPD and an eosinophilic phenotype, based on the BOREAS and NOTUS trials (FDA, 2024a).
Sanofi and Regeneron reported that more than 1 million patients had been treated with Dupixent globally by 2023. The patient base increased further during 2024 as use expanded in asthma, atopic dermatitis, eosinophilic esophagitis, and COPD (Sanofi, 2025).
What is the financial trajectory for Dupixent?
Dupixent has moved from a launch-stage product to Sanofi's largest growth asset.
| Fiscal year |
Dupixent sales |
Year-over-year growth |
Approximate share of Sanofi sales |
| 2020 |
€3.5 billion |
50% range |
10% |
| 2021 |
€5.2 billion |
48% |
15% |
| 2022 |
€8.3 billion |
43% |
21% |
| 2023 |
€10.7 billion |
35% |
25% |
| 2024 |
€13.1 billion |
22% |
32% |
Sources: Sanofi annual reports and financial releases.
Dupixent sales increased almost fourfold from 2020 to 2024. The growth rate has moderated as the revenue base expanded, but the product continues to grow at a rate that exceeds most mature pharmaceutical franchises.
Sanofi reported total 2024 sales of approximately €41.1 billion. Dupixent therefore represented roughly 32% of company revenue, making the product central to Sanofi's earnings profile. The product also supports Sanofi's transition toward specialty care after the company reduced emphasis on lower-growth consumer-health assets.
The financial model has three principal drivers:
- New indications increase the addressable population.
- Earlier-line use and pediatric approvals increase duration of therapy.
- International market penetration expands outside the United States.
Dupixent is generally used as chronic maintenance therapy. That creates recurring revenue, but it also increases exposure to payer restrictions, step edits, formulary competition, and treatment switching.
Which indications are driving dupilumab growth?
Atopic dermatitis remains the commercial foundation, but respiratory and gastrointestinal indications are increasing the franchise's durability.
Atopic dermatitis
Atopic dermatitis generated the initial commercial scale. Dupilumab established a systemic biologic category for moderate-to-severe disease and became a common treatment option for patients who failed or could not tolerate topical therapy.
The market is increasingly competitive. Oral Janus kinase inhibitors, including upadacitinib and abrocitinib, can offer rapid symptom relief and convenient administration. Their safety warnings and monitoring requirements, however, support continued use of dupilumab in patients for whom a favorable long-term safety profile is a priority.
Asthma and chronic rhinosinusitis
Asthma provides a large specialist market with multiple biologic alternatives. Dupilumab competes with benralizumab, mepolizumab, omalizumab, and tezepelumab. Its positioning is strongest in patients with type 2 inflammation, elevated eosinophils, coexisting atopic dermatitis, or chronic rhinosinusitis with nasal polyps.
The ability to treat several type 2 inflammatory diseases with one mechanism creates cross-indication prescribing advantages. Patients with asthma and atopic dermatitis, or asthma and nasal polyps, can remain within the same treatment franchise.
Eosinophilic esophagitis
Dupixent was the first FDA-approved biologic for eosinophilic esophagitis. The disease has historically been managed with dietary restrictions, swallowed corticosteroids, and proton-pump inhibitors. Dupilumab therefore entered a market with significant unmet need and limited biologic competition.
The main commercial constraint is the smaller diagnosed population compared with atopic dermatitis and asthma. The indication is important for price realization and franchise breadth rather than near-term volume comparable to the core markets.
COPD
The COPD approval is the most important late-stage expansion. Dupilumab was approved for a biomarker-defined population with uncontrolled disease despite standard inhaled therapy. The addressable population is smaller than the total COPD market, but treatment costs and disease burden are high.
Commercial execution will depend on:
- Identification of eosinophilic COPD patients.
- Payer acceptance of an injectable biologic in COPD.
- Evidence that treatment reduces exacerbations and healthcare utilization.
- Competition from inhaled triple therapy and emerging biologics.
COPD could add several billion euros in annual sales over time, but adoption will likely be slower than atopic dermatitis because diagnosis, biomarker testing, and treatment sequencing are more complex.
How does dupilumab compare with competing biologics?
Dupilumab has the broadest approved indication set among many type 2 inflammation biologics.
| Drug |
Company |
Main competitive areas |
Key differentiation |
| Dupilumab |
Sanofi/Regeneron |
Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, COPD |
Broadest cross-indication profile |
| Tralokinumab |
LEO Pharma |
Atopic dermatitis |
IL-13-only mechanism |
| Lebrikizumab |
Almirall/Eli Lilly |
Atopic dermatitis |
IL-13 pathway targeting |
| Tezepelumab |
AstraZeneca/Amgen |
Asthma |
Broad upstream TSLP inhibition |
| Benralizumab |
AstraZeneca |
Eosinophilic asthma |
IL-5 receptor targeting |
| Mepolizumab |
GSK |
Asthma, CRSwNP |
IL-5 targeting |
| Omalizumab |
Genentech/Novartis |
Allergic asthma, nasal polyps, food allergy |
IgE targeting |
| Upadacitinib |
AbbVie |
Atopic dermatitis and other inflammatory disease |
Oral JAK inhibitor |
| Abrocitinib |
Pfizer |
Atopic dermatitis |
Oral JAK inhibitor |
Dupilumab's competitive advantage is breadth rather than dominance in every individual disease. Cross-indication use, pediatric labeling, physician familiarity, and a substantial clinical database strengthen its position.
The main threats are:
- Oral JAK inhibitors with faster onset and no injection requirement.
- Biologics with more convenient dosing.
- Agents that target broader patient populations in asthma.
- Price competition as payers manage multiple biologic options.
- New biologics with improved efficacy in specific phenotypes.
When does dupilumab lose exclusivity?
Dupilumab has layered exclusivity involving the antibody, therapeutic uses, formulations, delivery systems, and manufacturing processes. The most important commercial question is the timing of biosimilar competition rather than a single patent expiration date.
Because Dupixent is a biologic, it is not governed by the small-molecule generic framework. FDA approval of a biosimilar would proceed under the Public Health Service Act's Section 351(k) pathway. Biosimilar applicants may seek approval for some or all reference-product indications, subject to regulatory and patent considerations (FDA, 2024b).
What patents protect dupilumab?
The relevant patent categories include:
- Antibodies that bind IL-4 receptor alpha.
- Antibody sequences and related biologic constructs.
- Treatment of atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, and other type 2 inflammatory conditions.
- Formulations that improve stability and shelf life.
- Subcutaneous delivery and prefilled-device configurations.
- Cell culture, purification, and manufacturing methods.
The foundational composition patents have earlier expiration dates than later formulation, dosing, and use patents. The resulting estate can delay practical biosimilar entry even after an early antibody patent expires.
Patent information for biologics is not presented through the Orange Book in the same manner as for conventional small-molecule drugs. The Purple Book identifies licensed biologics and biosimilar relationships but does not function as a complete Orange Book-style patent register. Patent disputes are handled through the BPCIA process and related federal litigation rather than through an automatic Hatch-Waxman stay (FDA, 2024c).
What is the likely biosimilar entry window?
No FDA-approved dupilumab biosimilar had been listed through the end of 2024. The practical entry window depends on:
- The earliest enforceable composition patent.
- Later formulation and use patents.
- The scope of Sanofi and Regeneron's BPCIA litigation.
- Whether a biosimilar applicant launches at risk.
- Settlement terms, if litigation produces an agreed entry date.
A commercial biosimilar launch is unlikely to be determined solely by the expiration of the earliest antibody patent. The strength of the secondary patent estate and manufacturing complexity will be more important.
Which companies are challenging dupilumab?
Publicly visible commercial competition is more significant than disclosed direct biosimilar litigation as of the end of 2024. The principal challengers are companies developing alternative mechanisms or competing biologics:
- AbbVie, through upadacitinib, competes strongly in atopic dermatitis.
- AstraZeneca competes in asthma through benralizumab and tezepelumab.
- GSK competes through mepolizumab in asthma and nasal polyps.
- Genentech and Novartis compete through omalizumab.
- LEO Pharma and Almirall compete in atopic dermatitis with IL-13 antibodies.
- Pfizer competes in atopic dermatitis through abrocitinib.
The market is therefore exposed to therapeutic substitution before it is exposed to conventional biosimilar erosion.
What is the FDA regulatory status of dupilumab?
Dupixent has full FDA approvals across several chronic inflammatory diseases, with labeling that includes adults, adolescents, and children in selected indications. Its regulatory trajectory has been unusually productive because the same mechanism applies across multiple type 2 inflammatory disorders.
The 2024 COPD approval is particularly valuable because it creates a new indication after the franchise had already reached multibillion-euro scale. It also differentiates Dupixent from several competitors that remain concentrated in asthma or dermatology.
FDA approvals include:
| Year |
Milestone |
| 2017 |
Atopic dermatitis |
| 2018 |
Asthma |
| 2019 |
Chronic rhinosinusitis with nasal polyps |
| 2022 |
Eosinophilic esophagitis |
| 2022 |
Prurigo nodularis |
| 2024 |
Eosinophilic COPD |
How strong is the dupilumab patent estate?
The estate is commercially strong because it has multiple layers and supports a biologic with high manufacturing complexity. Its strongest elements are likely the foundational antibody rights, disease-specific method-of-use claims, and late-filed formulation or device patents.
Its weaknesses are structural:
- Foundational patents age earlier than later secondary patents.
- Broad antibody claims can face validity challenges.
- Method-of-use claims may be narrower than composition claims.
- Biosimilar applicants can challenge patents while developing non-infringing manufacturing processes.
- Some indications may be vulnerable to skinny-label or partial-indication strategies.
The estate should be viewed as durable but not impenetrable. The key risk is a negotiated biosimilar settlement that permits entry before the full secondary patent portfolio expires.
What licensing deals support dupilumab economics?
Dupilumab originated from the collaboration between Regeneron and Sanofi. The companies jointly developed the product and share economics under their collaboration arrangements. Sanofi commercializes Dupixent globally, while Regeneron receives economic participation under the agreement.
The partnership reduces single-company development risk and gives Dupixent access to Sanofi's international commercial infrastructure. It also divides product economics, so Sanofi's reported product sales are not equivalent to its retained profit. Regeneron's participation is reflected through collaboration-related economics and profit-sharing arrangements described in company filings (Regeneron, 2025; Sanofi, 2025).
What generic and biosimilar launch risks exist?
The probability of rapid generic-style erosion is low because dupilumab is a complex antibody and cannot be substituted through an ordinary abbreviated new drug application.
The main launch scenarios are:
| Scenario |
Timing profile |
Commercial effect |
| No biosimilar challenge |
Extended protected growth |
Dupixent remains a high-growth specialty franchise |
| One biosimilar settlement |
Controlled entry after negotiated date |
Moderate price and volume pressure |
| Multiple biosimilars |
Competitive entry after patent disputes |
Faster net-price erosion |
| At-risk launch |
Early litigation-driven entry |
High volatility and potential damages |
| Therapeutic substitution |
Before biosimilar entry |
Share loss to JAK inhibitors or rival biologics |
Biosimilar erosion would likely be slower than for a small molecule but could still reduce net prices materially if several manufacturers enter. Pharmacy-benefit-manager contracting and payer formulary design would determine the speed of substitution.
What is the commercial outlook for dupilumab?
Dupilumab remains positioned for substantial revenue growth after 2024. The principal drivers are COPD penetration, earlier treatment in atopic dermatitis, pediatric expansion, international access, and increased diagnosis of eosinophilic esophagitis.
The growth curve will likely flatten from the historical 30% to 50% range as the product matures. The franchise has enough indication breadth to sustain multibillion-euro annual growth in the near term, but Sanofi's revenue concentration creates earnings sensitivity to:
- New indication uptake.
- Reimbursement pressure.
- Competitive switching.
- Manufacturing capacity.
- Patent litigation outcomes.
- Biosimilar launch timing.
A reasonable strategic assessment is that Dupixent will remain Sanofi's core growth product through the late 2020s, with the major value inflection coming from COPD and the major downside trigger coming from an accelerated biosimilar settlement or successful patent challenge.
Key Takeaways
- Dupilumab generated approximately €13.1 billion in 2024 sales.
- Dupixent represented about 32% of Sanofi's 2024 revenue.
- COPD is the most important new growth opportunity after the 2024 FDA approval.
- The product competes against biologics and oral JAK inhibitors across several disease areas.
- Biosimilar risk is governed by BPCIA litigation and layered patent protection, not ordinary generic substitution.
- The patent estate includes composition, use, formulation, device, and manufacturing claims.
- No FDA-approved dupilumab biosimilar was listed through the end of 2024.
- Sanofi's principal financial risk is revenue concentration in a single high-value biologic franchise.
FAQs About Dupilumab Market and Patent Risk
How much revenue does Dupixent generate for Sanofi?
Dupixent generated approximately €13.1 billion in Sanofi sales in 2024, making it the company's largest individual growth product.
Is dupilumab a biologic or a small-molecule drug?
Dupilumab is a fully human monoclonal antibody biologic. It is administered by subcutaneous injection and is regulated under the Public Health Service Act.
Can a generic company substitute for Dupixent?
No. Conventional generic substitution is not available for dupilumab. A competitor would need FDA approval through the 351(k) biosimilar pathway or another biologic approval route.
Does Dupixent have an Orange Book patent listing?
Dupixent is a biologic and is not listed in the Orange Book in the same way as a conventional small-molecule drug. Relevant patent disputes proceed under the BPCIA framework and federal patent law.
Which new Dupixent indication has the largest future value?
COPD has the largest potential incremental value because it opens a large respiratory market. Actual uptake will depend on biomarker testing, payer coverage, and competition from inhaled therapies and other biologics.
References
-
Food and Drug Administration. (2024a). FDA approves Dupixent as add-on maintenance treatment in adults with uncontrolled COPD and an eosinophilic phenotype. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024b). Biosimilar and interchangeable biosimilar products. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024c). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
Regeneron Pharmaceuticals, Inc. (2025). 2024 annual report. Tarrytown, NY.
-
Sanofi. (2025). 2024 universal registration document and annual financial report. Paris, France.
-
Sanofi and Regeneron Pharmaceuticals, Inc. (2024). Dupixent prescribing information. U.S. Food and Drug Administration.
